Interferon and vinblastine in advanced renal carcinoma
Vicini, D.; Franceschetti, G.P.; Mirando, P.; Ruggieri, M.; Cardellini, P.
Archivio Italiano di Urologia Andrologia Organo Ufficiale di Societa Italiana di Ecografia Urologica e Nefrologica 65(2): 181-184
1993
ISSN/ISBN: 1124-3562 PMID: 8330065 Document Number: 415041
19 patients with renal adenocarcinoma and mets were treated with INF alfa 2b (10 x 10(6) U/m square s.c. three times weekly) plus VBL (0.1 mg/kg every 3 weeks). We followed up the patients for 12 weeks with monitoring of major parameters. The outcomes have been positive in 16.6% of the cases with mean survival of 20.7 months. We point out the efficacy in lung mets. The outcomes of therapy with INF alfa 2b plus VBL are unsuccessful and we state that an alternative solution could be interleukin 2.